1.99

0.50% -0.01

After Hours: 2.02 0.03 +1.51%

Palisade Bio Inc (PALI)

Overview News Price History Financials Discussions Forecast Stock Split

Palisade Bio Inc stock is traded at $1.99, with a volume of 2.78M. It is down -0.50% in the last 24 hours and up +5.85% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Previous Close:

$2.00

Open:

$2.01

24h Volume:

2.78M

Relative Volume:

0.71

Market Cap:

$333.57M

Revenue:

$250.00K

Net Income/Loss:

$-16.78M

P/E Ratio:

-1.3402

EPS:

-1.4848

Net Cash Flow:

$-10.85M

1W Performance:

-4.33%

1M Performance:

+5.85%

6M Performance:

-3.86%

1Y Performance:

+154.93%

1-Day Range:

$1.90

$2.01

1-Week Range:

$1.90

$2.175

52-Week Range:

$0.53

$2.855

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

(858) 704-4900

Address

7750 EL CAMINO REAL, SUITE 5200, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

PALI's Discussions on Twitter

Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PALI Palisade Bio Inc	1.99	333.57M	250.00K	-16.78M	-10.85M	-1.4848
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Palisade Bio Inc Stock (PALI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-26-26	Initiated	H.C. Wainwright	Buy
Feb-25-26	Initiated	Stifel	Buy
Jan-09-26	Initiated	B. Riley Securities	Buy
Dec-29-25	Initiated	Piper Sandler	Overweight

Palisade Bio Inc Stock (PALI) Latest News

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN

Apr 30, 2026

Apr 29, 2026

Major share increase and equity plan votes ahead for Palisade Bio (NASDAQ: PALI) - Stock Titan

Apr 29, 2026

Apr 28, 2026

PALI Palisade Bio posts narrower than expected Q4 2025 loss, shares gain more than four percent.Secondary Offering - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 21, 2026

Analysts Offer Predictions for Palisade Bio Q1 Earnings - MarketBeat

Apr 21, 2026

Apr 20, 2026

Brokers Issue Forecasts for Palisade Bio Q3 Earnings - MarketBeat

Apr 20, 2026

Apr 17, 2026

Palisade Bio (NASDAQ: PALI) asks shareholders to lift authorized shares to 450M - Stock Titan

Apr 17, 2026

Palisade Bio Develops Crohn’s Disease Treatment Following Positive Study - HarianBasis.co

Apr 17, 2026

Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Insider Monkey

Apr 17, 2026

Palisade Bio to present ulcerative colitis data at DDW conference By Investing.com - Investing.com India

Apr 17, 2026

Apr 16, 2026

Palisade Bio to present ulcerative colitis data at DDW conference - Investing.com

Apr 16, 2026

Palisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative Colitis - Quiver Quantitative

Apr 16, 2026

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 - GlobeNewswire

Apr 16, 2026

5 Best Biotech Stocks Under $10 to Buy - Insider Monkey

Apr 16, 2026

Apr 13, 2026

Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com South Africa

Apr 13, 2026

Piper Sandler reiterates Overweight rating on Palisade Bio stock - Investing.com

Apr 13, 2026

Apr 11, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 11, 2026

Apr 10, 2026

Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Apr 10, 2026

Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy - MarketBeat

Apr 10, 2026

Apr 09, 2026

Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI) - MarketBeat

Apr 09, 2026

Apr 08, 2026

Palisade Bio CEO, CMO to give virtual Needham presentation April 16 - Stock Titan

Apr 08, 2026

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - The Manila Times

Apr 08, 2026

Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN

Apr 08, 2026

Is Palisade Bio (PALI) Stock a future winner | Price at $1.94, Up 1.31%Trending Social Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 08, 2026

Apr 07, 2026

Earnings Miss: Can Palisade Bio Inc expand its profit margins2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn

Apr 07, 2026

Apr 05, 2026

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail

Apr 05, 2026

Apr 02, 2026

Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks

Apr 02, 2026

Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com Australia

Apr 02, 2026

Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView

Apr 02, 2026

Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan

Apr 02, 2026

Apr 01, 2026